Sales & Marketing

Kyowa Kirin now leads the commercial efforts for Crysvita in 40 countries, continuing its commitment to address the needs of people living with rare diseases.

Biogen Inc. announced the approval, a groundbreaking treatment for adults with ALS, offering hope to patients suffering from SOD1-ALS, a rare and fatal genetic form of the disease.

Seres Therapeutics and Nestlé Health Science celebrate the FDA's approval of Vowst, a first-of-its-kind orally administered microbiota-based therapeutic set to transform the lives of patients with recurrent C. difficile infections.

First once-every-two-months long-acting injectable offers sustained therapeutic concentrations for patients.

Industry leaders threaten to devote resources elsewhere.

Christopher Boerner, chief commercialization officer, set to succeed Caforio in November.

Join host Fran Pollaro as he delves into the world of patient-centric dermatology innovations with Arcutis president and CEO Frank Watanabe in this Pharmaceutical Executive Podcast episode.

Digital and innovation leader takes issue with the current state of pharma marketing and suggests new approaches are needed.

Eli Lilly offloads innovative hypoglycemia nasal spray, Baqsimi, to Amphastar Pharmaceuticals bolstering Amphastar's diabetes portfolio.

Cost Plus Drug Co. adds J&J's Janssen medications to its offerings, increasing affordability for diabetes patients.

Webinar Date/Time: Thu, May 18, 2023 11:00 AM EDT

The $10.8 billion deal positions Merck to acquire promising immune-disorder therapies.

J&J's Janssen Pharmaceutica NV collaborates with Pipeline Therapeutics in a $50 million licensing deal for oral MS drug PIPE-307, with potential earnings of up to $1 billion for Pipeline.

By tailoring messages, leveraging digital channels, creating personalized experiences, and fostering relationships, healthcare marketers can connect with HCPs across generations and build lasting partnerships.

It’s time for pharma brands to recognize the potential of TikTok as a promotional platform and develop a strategy to not only stand out but make an impact.

Bankrupt Clovis Oncology offloads assets, including ovarian cancer drug Rubraca, to Swiss firm Pharma& Schweiz for over $70 million.

Regardless of engagement mode pursued, personalization is the key.

As the Biden Administration transitions Covid-19-related costs to public and private markets, Moderna is increasing its vaccine price from $26 to $130 per dose.

Eli Lilly debuts its first Mounjaro TV commercial amid high demand for the diabetes injection, which also shows promise in weight loss applications and outperformed rivals Ozempic and Wegovy in clinical trials.

Fingerpaint Group further enforces its commitment to the space, marking its second market access acquisition in three years.

How to build a modular content system to optimize content creation and delivery, Using Al-powered engines that know your HCP's viewing behavior, using discomfort as an advantage and much more.

How media consumption is evolving and modifying digital and social strategies to best capture the behavioral changes of HCPs towards digital platforms.

EVERSANA honored for innovative use of artificial intelligence in video production — enhancing educational content development for the life science industry.

The combined company is expected to deliver a superior health care experience and drive better outcomes.

Rohit Gupta, vice president of analytics strategy and transformation at Beghou Consulting, addresses the controversial middlemen of the drug pricing world, the pharmacy benefit managers (PBMs). Can increased competition and other innovative solutions loosen their grip and prevent further consolidation?